Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $21.10

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned a consensus rating of “Buy” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $21.10.

A number of research analysts have recently commented on TRVI shares. D. Boral Capital restated a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Friday, January 9th. Morgan Stanley increased their price target on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. Finally, Leerink Partners boosted their price objective on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th.

Trevi Therapeutics Trading Down 2.6%

Shares of TRVI opened at $10.48 on Monday. Trevi Therapeutics has a 1-year low of $3.47 and a 1-year high of $14.39. The firm’s 50-day moving average price is $12.21 and its 200-day moving average price is $9.74. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -28.32 and a beta of 0.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. On average, research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Alliancebernstein L.P. raised its stake in Trevi Therapeutics by 19,064.5% during the second quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company’s stock valued at $23,419,000 after buying an additional 4,259,015 shares during the last quarter. Rubric Capital Management LP grew its stake in shares of Trevi Therapeutics by 88.0% in the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after acquiring an additional 3,993,325 shares during the last quarter. Viking Global Investors LP grew its stake in shares of Trevi Therapeutics by 232.4% in the third quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after acquiring an additional 3,585,875 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Trevi Therapeutics by 1,792.0% during the third quarter. Wellington Management Group LLP now owns 3,253,888 shares of the company’s stock valued at $29,773,000 after acquiring an additional 3,081,906 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Trevi Therapeutics by 95.4% in the 3rd quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock worth $44,302,000 after purchasing an additional 2,363,835 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.